What are the cancer indications, standard drug doses, administration schedules, and key differences among the FOLFOX (folinic acid, fluorouracil, oxaliplatin) regimens—including FOLFOX-4, FOLFOX-6, FOLFOX-7, modified FOLFOX-6 (mFOLFOX-6), and other common variants?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

FOLFOX Chemotherapy Regimens: Comprehensive Explanation

The FOLFOX family consists of several variants that differ primarily in oxaliplatin dosing, leucovorin formulation, and 5-FU administration schedules, with mFOLFOX-6 now established as the preferred regimen for both adjuvant and metastatic colorectal cancer treatment. 1, 2, 1


1. Cancer Indications by Regimen

FOLFOX-4

  • Stage III colon cancer (adjuvant): Category 1 recommendation based on MOSAIC trial 1, 3
  • Metastatic colorectal cancer (first-line): Demonstrated superiority over 5-FU/LV alone 4
  • Clinical setting: Historically used but largely replaced by mFOLFOX-6 in current practice 1

mFOLFOX-6 (Modified FOLFOX-6)

  • Stage III colon cancer (adjuvant): Preferred FOLFOX regimen, Category 1 1, 5
  • High-risk Stage II colon cancer (adjuvant): Reasonable option for patients with poor prognostic features 1, 5
  • Metastatic colorectal cancer: Standard first-line therapy 5, 6, 7
  • Clinical setting: Control arm for all recent NCI adjuvant studies; preferred over FOLFOX-4 1

FOLFOX-6

  • Metastatic colorectal cancer (second-line): After failure of first-line therapy 8
  • Clinical setting: Less commonly used variant, primarily in Japanese studies 8

FOLFOX-7

  • Metastatic colorectal cancer: Investigated in dose-dense strategies with intermittent oxaliplatin 9, 10
  • Clinical setting: Not standard; used in specific protocols exploring oxaliplatin-free intervals to reduce neuropathy 10

2. Drug Doses by Regimen

FOLFOX-4 2, 3, 4

  • Oxaliplatin: 85 mg/m² IV over 2 hours, Day 1
  • Leucovorin: 200 mg/m² IV over 2 hours, Days 1 and 2
  • 5-FU bolus: 400 mg/m² IV bolus, Days 1 and 2
  • 5-FU infusion: 600 mg/m² IV over 22 hours, Days 1 and 2
  • Cycle: Every 14 days

mFOLFOX-6 2, 5, 1, 5, 4

  • Oxaliplatin: 85 mg/m² IV over 2 hours, Day 1
  • Leucovorin: 400 mg/m² IV over 2 hours, Day 1 (or levo-leucovorin 200 mg/m²)
  • 5-FU bolus: 400 mg/m² IV bolus, Day 1
  • 5-FU infusion: 2,400 mg/m² continuous IV over 46-48 hours (1,200 mg/m²/day × 2 days)
  • Cycle: Every 14 days

FOLFOX-6 8

  • Oxaliplatin: 100 mg/m² IV over 2 hours, Day 1
  • L-Leucovorin: 200 mg/m² IV over 2 hours, Day 1
  • 5-FU bolus: 400 mg/m² IV bolus, Day 1
  • 5-FU infusion: 2,400 mg/m² continuous IV over 46 hours
  • Cycle: Every 14 days

FOLFOX-7 9, 10

  • Oxaliplatin: 130 mg/m² IV over 2 hours, Day 1
  • Levo-leucovorin: 200 mg/m² IV over 2 hours, Day 1
  • 5-FU infusion: 2,400 mg/m² continuous IV over 46-48 hours (NO bolus)
  • Cycle: Every 14 days

3. Administration Schedule Details

mFOLFOX-6 (Standard Protocol) 2, 5, 1, 4

Sequence:

  1. Oxaliplatin 85 mg/m² and leucovorin 400 mg/m² administered concurrently via Y-connector over 2 hours, Day 1
  2. Immediately followed by 5-FU 400 mg/m² IV bolus
  3. Then 5-FU 1,200 mg/m²/day continuous infusion over 46-48 hours (total 2,400 mg/m²)

Treatment Duration:

  • Adjuvant setting: 12 cycles (6 months total) 11, 5, 4
  • Metastatic setting: Continue until disease progression or unacceptable toxicity 4

Important Safety Note: Orders should specify 24-hour units (1,200 mg/m²/day) rather than total dose over 48 hours to minimize medication errors 2, 1

FOLFOX-4 Administration 2, 3

Day 1:

  • Oxaliplatin 85 mg/m² IV over 2 hours
  • Leucovorin 200 mg/m² IV over 2 hours (can be concurrent with oxaliplatin)
  • 5-FU 400 mg/m² IV bolus
  • 5-FU 600 mg/m² continuous infusion over 22 hours

Day 2:

  • Leucovorin 200 mg/m² IV over 2 hours
  • 5-FU 400 mg/m² IV bolus
  • 5-FU 600 mg/m² continuous infusion over 22 hours

Cycle interval: Every 14 days

FOLFOX-7 Administration 9, 10

Key difference: Eliminates 5-FU bolus entirely

  • Oxaliplatin 130 mg/m² and levo-leucovorin 200 mg/m² over 2 hours, Day 1
  • 5-FU 2,400 mg/m² continuous infusion over 46-48 hours only
  • Cycle every 14 days

4. Key Differences Between Regimens

FOLFOX-4 vs. mFOLFOX-6

Feature FOLFOX-4 mFOLFOX-6
Hospital visits Twice weekly (Days 1 and 2) Once every 2 weeks
Oxaliplatin dose 85 mg/m² 85 mg/m²
5-FU bolus 400 mg/m² × 2 days (800 mg/m² total) 400 mg/m² × 1 day
5-FU infusion 600 mg/m² × 22h × 2 days (1,200 mg/m² total) 2,400 mg/m² over 46-48h
Total 5-FU per cycle 2,000 mg/m² 2,800 mg/m²
Leucovorin 200 mg/m² × 2 days 400 mg/m² × 1 day
Convenience Less convenient More convenient [1,8]
Current use Largely replaced Preferred standard [1]

FOLFOX-6 vs. mFOLFOX-6

Feature FOLFOX-6 mFOLFOX-6
Oxaliplatin dose 100 mg/m² 85 mg/m²
5-FU bolus 400 mg/m² 400 mg/m²
5-FU infusion 2,400 mg/m² 2,400 mg/m²
Leucovorin form L-leucovorin 200 mg/m² Leucovorin 400 mg/m² or levo-leucovorin 200 mg/m²
Geographic use Primarily Japan [8] Worldwide standard

FOLFOX-7 vs. mFOLFOX-6

Feature FOLFOX-7 mFOLFOX-6
Oxaliplatin dose 130 mg/m² (higher) 85 mg/m²
5-FU bolus None 400 mg/m²
5-FU infusion 2,400 mg/m² 2,400 mg/m²
Rationale Dose-dense oxaliplatin with planned breaks [10] Continuous standard dosing
Neuropathy strategy Intermittent administration (6 cycles on, 12 off, then reintroduce) [10] Continuous until toxicity
Standard use Investigational only [9,10] Standard of care

5. Modified FOLFOX-6 Variants

Standard mFOLFOX-6 with Bevacizumab 5, 6

  • Add bevacizumab 5 mg/kg IV Day 1 every 2 weeks (metastatic setting)
  • All other doses remain identical

Duration-Modified mFOLFOX-6 (IDEA Study) 11, 5

For adjuvant treatment:

  • Low-risk Stage III (T1-3N1): Consider 3 months (6 cycles) of CAPEOX preferred over 3 months mFOLFOX-6
  • High-risk Stage III (T4 or N2): 6 months (12 cycles) remains standard
  • Rationale: Reduces cumulative neuropathy without compromising efficacy in selected patients 11

6. Common Pitfalls and Caveats

Leucovorin Formulation 1, 2, 1

  • Leucovorin 400 mg/m² = Levo-leucovorin 200 mg/m² (equipotent doses)
  • During leucovorin shortages, lower doses (20-200 mg/m²) show similar efficacy 1
  • Treatment without leucovorin is reasonable if unavailable, with 10% 5-FU dose increase if tolerated 1

Neuropathy Management 1, 3, 7

  • Grade 3 peripheral sensory neuropathy occurs in 12-17% with FOLFOX 1, 3
  • Persists in 15% at 4 years (mostly grade 1) 1
  • Avoid ice application to extremities during oxaliplatin infusion 4
  • Calcium/magnesium infusions are not recommended for neuropathy prevention 7

Age Considerations 12, 5

  • Benefits of oxaliplatin-containing regimens are more limited in patients ≥70 years 5
  • No evidence that adding oxaliplatin benefits patients aged ≥70 in adjuvant setting 5
  • Consider fluoropyrimidine monotherapy in elderly patients 7

Dosing Error Prevention 2, 1

  • Always order 5-FU as 1,200 mg/m²/day × 2 days, NOT as 2,400 mg/m² over 46-48 hours
  • This prevents potentially fatal overdosing errors 2, 1

Regimens NOT Recommended 1, 5

  • FLOX (bolus 5-FU/LV/oxaliplatin): Higher diarrhea rates, not preferred 1, 3
  • Bevacizumab, cetuximab, panitumumab, irinotecan: Should NOT be used in adjuvant setting outside clinical trials 1, 5

7. Treatment Timing

Adjuvant Therapy 5

  • Initiate within 3 weeks postoperatively when medically able
  • Must start no later than 2 months after surgery
  • Delays beyond 8 weeks result in 14% decrease in overall survival 1

Metastatic Setting 4

  • Continue until disease progression or unacceptable toxicity
  • Consider intermittent strategies (oxaliplatin breaks) after 6 cycles to reduce neuropathy 7, 10

References

Guideline

colon cancer.

Journal of the National Comprehensive Cancer Network : JNCCN, 2011

Guideline

nccn clinical practice guidelines in oncology: colon cancer.

Journal of the National Comprehensive Cancer Network : JNCCN, 2009

Guideline

treatment of metastatic colorectal cancer: asco guideline.

Journal of Clinical Oncology, 2023

Guideline

colon cancer, version 2.2021, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2021

Research

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.